Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Valacyclovir + aspirin is a non-branded combination of two well-established drugs, valacyclovir and aspirin, administered together. Valacyclovir is an oral antiviral prodrug that is rapidly converted to acyclovir in the body; it inhibits viral DNA polymerase, thereby blocking replication of herpesviruses such as HSV-1, HSV-2, and varicella-zoster virus. Aspirin (acetylsalicylic acid) is a nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis to provide analgesic, antipyretic, anti-inflammatory effects and inhibit platelet aggregation. The combination has been studied for potential additive or synergistic effects in certain contexts—such as reducing herpesvirus shedding—but available evidence does not show significant benefit over monotherapy with valacyclovir for this purpose[2]. Both agents are widely used individually for their respective indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on valacyclovir + aspirin.